Testing a new antibody drug for advanced solid cancers

Plain-English translation of NCT07169734 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

This is one of the first times this treatment has been tested in people.

What is this trial?

This trial is testing a new cancer medication called , which is designed to target cancer cells that have a specific protein on their surface called Claudin-1. The study has two main phases: first, doctors will gradually increase the dose to find the safest and most effective amount, and then they will test that dose in more patients to see how well the medication works against several types of advanced cancer.

Many patients with advanced cancers like lung, colorectal, cervical, bladder, and bile duct cancers do not respond well to existing treatments or cannot tolerate them. This medication offers a new approach by targeting a protein found on certain cancer cells, potentially helping patients who have run out of other options.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced or metastatic cancer (such as colorectal, lung, cervical, bladder, or bile duct cancer) that has spread or is worsening
your cancer cells have been tested and confirmed to have the Claudin-1 protein marker
you have already received and did not benefit from, or could not tolerate, at least one previous standard cancer treatment
your cancer has shown growth on imaging scans before starting the study
you are in good enough general health to tolerate the treatment (performance status 0 or 1)
your blood counts and organ function are adequate, as shown by blood tests

You likely don't qualify if…

you have cancer that has spread to your brain or the lining of your spinal cord
you have a history of serious lung inflammation or scarring that required steroids
you have active bleeding in your stomach or intestines
you have an active infection requiring antibiotics or other systemic treatment
you received other cancer treatments very recently (within a specified timeframe before starting this study)

What participation looks like

You will receive the medication through an intravenous infusion (a vein in your arm) at scheduled visits. The study has different phases: in Phase I, the dose will be gradually increased in small groups of patients to find the safest level; in Phase II, more patients will receive the established safe dose to evaluate how well it works. Throughout the trial, you will have regular blood tests, imaging scans, and check-ups to monitor how you are responding and to watch for side effects.

AI-generated summary from trial data · Jul 3, 2026 · Not medical advice

Trial locations(41 sites)

United States

Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona

USC Norris Comprehensive Cancer Center, Los Angeles, California

Yale Comprehensive Cancer Center, New Haven, Connecticut

The University of Chicago Medical Center - Oncology, Chicago, Illinois

Norton Cancer Institute - Norton Healthcare Pavilion, Louisville, Kentucky